SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and ACADIA Pharmaceuticals Inc.

SG&A Trends: Jazz vs. ACADIA Pharmaceuticals

__timestampACADIA Pharmaceuticals Inc.Jazz Pharmaceuticals plc
Wednesday, January 1, 201432748000406114000
Thursday, January 1, 201590804000449119000
Friday, January 1, 2016186456000502892000
Sunday, January 1, 2017255062000544156000
Monday, January 1, 2018265758000683530000
Tuesday, January 1, 2019325638000736942000
Wednesday, January 1, 2020388661000854233000
Friday, January 1, 20213960280001451683000
Saturday, January 1, 20223690900001416967000
Sunday, January 1, 20234024660001343105000
Loading chart...

Unlocking the unknown

SG&A Efficiency: A Tale of Two Pharmaceuticals

In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, Jazz Pharmaceuticals plc and ACADIA Pharmaceuticals Inc. have shown distinct trajectories in their SG&A efficiency.

Jazz Pharmaceuticals plc: A Steady Climb

From 2014 to 2023, Jazz Pharmaceuticals saw a consistent increase in SG&A expenses, peaking in 2021 with a 258% rise from 2014. This growth reflects their aggressive expansion and investment in administrative capabilities.

ACADIA Pharmaceuticals Inc.: A Gradual Rise

ACADIA Pharmaceuticals, on the other hand, experienced a more moderate increase, with a 1,129% rise in SG&A expenses from 2014 to 2023. This suggests a strategic focus on scaling operations while maintaining cost efficiency.

Conclusion

Understanding these trends provides valuable insights into each company's strategic priorities and operational efficiencies, offering a window into their future growth potential.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025